Goldman Sachs Group Inc. Has $751,000 Stock Position in Caribou Biosciences, Inc. $CRBU

Goldman Sachs Group Inc. lowered its position in Caribou Biosciences, Inc. (NASDAQ:CRBU) by 23.1% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 822,840 shares of the company’s stock after selling 247,696 shares during the period. Goldman Sachs Group Inc. owned about 0.88% of Caribou Biosciences worth $751,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CRBU. Northern Trust Corp boosted its holdings in shares of Caribou Biosciences by 3.4% in the fourth quarter. Northern Trust Corp now owns 714,737 shares of the company’s stock valued at $1,136,000 after buying an additional 23,531 shares during the period. Ameriprise Financial Inc. acquired a new stake in Caribou Biosciences in the fourth quarter valued at $649,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Caribou Biosciences by 4.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 176,654 shares of the company’s stock valued at $281,000 after purchasing an additional 8,199 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Caribou Biosciences by 52.9% during the 4th quarter. Millennium Management LLC now owns 859,825 shares of the company’s stock worth $1,367,000 after acquiring an additional 297,351 shares during the period. Finally, Nuveen Asset Management LLC increased its holdings in shares of Caribou Biosciences by 23.6% in the fourth quarter. Nuveen Asset Management LLC now owns 330,831 shares of the company’s stock valued at $526,000 after purchasing an additional 63,096 shares during the last quarter. 77.51% of the stock is currently owned by institutional investors.

Caribou Biosciences Trading Down 3.6%

Shares of CRBU stock opened at $1.86 on Wednesday. The stock has a market cap of $173.20 million, a price-to-earnings ratio of -1.04 and a beta of 2.54. Caribou Biosciences, Inc. has a 1-year low of $0.66 and a 1-year high of $3.00. The stock has a 50-day moving average of $1.93 and a 200-day moving average of $1.35.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.05. Caribou Biosciences had a negative return on equity of 62.35% and a negative net margin of 1,800.93%.The business had revenue of $2.67 million during the quarter, compared to analysts’ expectations of $1.64 million. Sell-side analysts forecast that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Analyst Ratings Changes

Separately, Wall Street Zen raised Caribou Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 24th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $6.67.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.